Raptor Pharmaceutical cancels $75 million at-the-market agreement

Offering with Cowen terminated because company doesn’t plan to use it

By Devika Patel

Knoxville, Tenn., July 7 – Raptor Pharmaceutical Corp. terminated a $75 million at-the-market sales agreement with agent Cowen and Co., LLC on July 5, according to an 8-K filed Thursday with the Securities and Exchange Commission. The deal priced on April 30, 2013 and was increased from $40 million on July 3, 2013.

The company said the agreement was terminated because it does not plan to use the program.

Raptor is a Novato, Calif., biotechnology company that bioengineers novel drugs and drug-targeting platforms derived from the human receptor-associated protein and related proteins.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.